Background: New antiretroviral (ARV) drugs and improved formulations and coformulations of existing ARVs are actively promoted to diminish a patient's pill burden and to minimise the opportunity for mismatched dosing, although the effect of these advances is poorly understood. We determine how these changes affect the total daily pill burden (TDPB) for ARV and other drug use over a 20-year period.
Methods: Using our in-house pharmacy database, we calculated the daily number and associated pill burden of oral ARV and non-ARV (prescription and over-the-counter) medications taken by every patient within the Southern Alberta Cohort (SAC) between 1990 and 2010. We compared the mean TDPB with the patients' sociodemographic and clinical characteristics.
Results: Mean TDPB for ARV-experienced patients increased from 4.9 in 1990 to 12.1 in 1998 but decreased to 6.7 in 2010. By 2010, new ARVs and newer formulations had decreased ARV pill burden by 50% over five years. In 1990, however, 95% of the TDPB consisted of ARVs but by 2010 it fell to 51% as non-ARV daily drugs increased from 0.2 in 1990 to 2.6 in 2010. Variation in TDPB was attributable to four main factors: patient's age, risk factor, nadir CD4(+) T-cell count and duration of known HIV infection.
Conclusions: While new ARV formulations and coformulations have simplified regimens, this reduction in ARV pill burden has been counterbalanced by increases in non-ARV drugs required for managing comorbidities. Discussions on merits of coformulations in decreasing ARV pill burden need to include the non-ARV pill burden.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3851/IMP2076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics.
BMC Pulm Med
January 2025
Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Objective: Lung cancer (LC), the primary cause for cancer-related death globally is a diverse illness with various characteristics. Saliva is a readily available biofluid and a rich source of miRNA. It can be collected non-invasively as well as transported and stored easily.
View Article and Find Full Text PDF[Analysis and prediction of the age-period-cohort model of disease burden of rheumatoid arthritis in China from 1990 to 2019].
Zhonghua Nei Ke Za Zhi
February 2025
Department of Rheumatology, the First Affiliated Hospital of Harbin Medical University, Harbin150001, China.
Using the Global Burden of Disease Study 2019 (GBD 2019) database, the Joinpoint regression model was used to analyze the trend of rheumatoid arthritis (RA) incidence and the standardized disability-adjusted life years (DALY) rate in China. The age, period, and cohort effects were discussed based on the age-period-cohort model. The grey prediction model GM (1, 1) was used to fit the trend of incidence and the standardized DALY rate of RA and predict the incidence and standardized DALY rate of RA in China from 2020 to 2034.
View Article and Find Full Text PDFAssessing the Burden of Neglected Tropical Diseases in Low-Income Communities: Challenges and Solutions.
Viruses
December 2024
Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.
Neglected tropical diseases (NTDs) represent a group of chronic and debilitating infections that affect more than one billion people, predominantly in low-income communities with limited health infrastructure. This paper analyzes the factors that perpetuate the burden of NTDs, highlighting how poor health infrastructure, unfavorable socioeconomic conditions and lack of therapeutic resources exacerbate their impact. The effectiveness of current interventions, such as mass drug administration (MDA) programs and improved sanitation, in reducing disease prevalence is examined.
View Article and Find Full Text PDFGlobal trends in the burden of ischemic heart disease based on the global burden of disease study 2021: the role of metabolic risk factors.
BMC Public Health
January 2025
Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.
Background: Ischemic heart disease (IHD) remains a leading cause of mortality and morbidity globally. This study aims to evaluate the trends in IHD burden across different socioeconomic regions using data from the Global Burden of Disease Study 2021 (GBD 2021) and to understand the impact of the metabolic risk factors on these trends.
Methods: Data from GBD 2021 was analyzed to evaluate the global age-standardized death rates (ASDR) and disability-adjusted life years (ASRDALYs) linked to IHD.
Burden and mortality of breast cancer attributed to diabetes and smoking in women: a secondary analysis based on Global Burden of Disease 2019 in North Africa and the Middle East.
BMJ Open
January 2025
Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Background: Breast cancer (BC) is the second most common cancer in the world. This study aimed to investigate the burden of BC due to some risk factors in the Middle East and North Africa (MENA) countries from 1990 to 2019.
Methods: This study is a secondary analysis based on the Global Burden of Disease 2019 data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!